Grant: Health System Impact Fellowships - Doctoral Western Canada 1-year
University of British Columbia
$17,500.00
The real-world impact of ETI on prescribing patterns, clinical outcomes, and healthcare utilization for PwCF living in British Columbia
EF 2023-24
Résumé
Cystic fibrosis (CF) is the most common fatal genetic disease, affecting ~1 in 3600 children born in Canada. BC has one of the highest incidence rates in Canada. Treatment is complex, involving multiple medications and treatments. A recent game-changing therapy, known as ETI (brand name: Trikafta®) can improve lung function, slow disease progression, and improve the quality of life for People with CF (PwCF). ETI has been studied as an add-on therapy to inhaled respiratory treatments, which can take hours to administer every day. As symptoms improve on ETI, PwCF often cuts down on these time-consuming treatments, but it remains unknown whether stopping inhaled therapies has detrimental effects. Our study aims to evaluate how ETI therapy has led to changes in medication use, lung function, and healthcare utilization such as clinic visits. We will analyze data from PwCF who have started ETI therapy, comparing them to themselves before starting treatment, to individuals not eligible for ETI, and to healthy individuals without CF. Our research is groundbreaking as we will use connected data from various sources to study how this new treatment affects CF care. We aim to fill a knowledge gap about what happens when PwCF stop using older treatments while receiving ETI, and how this might affect their health outcomes and healthcare utilization. The anticipated outcomes include valuable insights into personalized treatment, improving the quality of life for PwCF, and reducing strain on the Canadian healthcare system. By investigating the real-world impact of ETI on respiratory therapy refills, outcomes, and healthcare utilization, the study will provide essential information to healthcare providers and policymakers, ensuring the most effective and efficient allocation of resources for CF management. It will contribute significantly to the field by enabling more personalized treatment decisions and improving the overall understanding of CF treatment in a real-world context.
Programme
Health System Impact Fellowships - Doctoral Western Canada 1-year
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
503445
Name
Jafari Mehdi
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Michael Smith Health Research BC
Instname2
Population and Public Health
Theme2
Clinical
Prcname2
Fellowship : Health System Impact Fellowship Doctoral
Projecttitle
The real-world impact of ETI on prescribing patterns, clinical outcomes, and healthcare utilization for PwCF living in British Columbia
Programtype2
Fellowship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Health System Impact Fellowships - Doctoral Western Canada 1-year
Keyworddelim
Clinical Outcomes; Cystic Fibrosis; Eti (Elexacaftor/Tezacaftor/Ivacaftor); Healthcare Utilization; Prescribe Patterns; Pwcf (People With Cystic Fibrosis); Real-World Impact; Trikafta
Abstract
Cystic fibrosis (CF) is the most common fatal genetic disease, affecting ~1 in 3600 children born in Canada. BC has one of the highest incidence rates in Canada. Treatment is complex, involving multiple medications and treatments. A recent game-changing therapy, known as ETI (brand name: Trikafta®) can improve lung function, slow disease progression, and improve the quality of life for People with CF (PwCF). ETI has been studied as an add-on therapy to inhaled respiratory treatments, which can take hours to administer every day. As symptoms improve on ETI, PwCF often cuts down on these time-consuming treatments, but it remains unknown whether stopping inhaled therapies has detrimental effects. Our study aims to evaluate how ETI therapy has led to changes in medication use, lung function, and healthcare utilization such as clinic visits. We will analyze data from PwCF who have started ETI therapy, comparing them to themselves before starting treatment, to individuals not eligible for ETI, and to healthy individuals without CF. Our research is groundbreaking as we will use connected data from various sources to study how this new treatment affects CF care. We aim to fill a knowledge gap about what happens when PwCF stop using older treatments while receiving ETI, and how this might affect their health outcomes and healthcare utilization. The anticipated outcomes include valuable insights into personalized treatment, improving the quality of life for PwCF, and reducing strain on the Canadian healthcare system. By investigating the real-world impact of ETI on respiratory therapy refills, outcomes, and healthcare utilization, the study will provide essential information to healthcare providers and policymakers, ensuring the most effective and efficient allocation of resources for CF management. It will contribute significantly to the field by enabling more personalized treatment decisions and improving the overall understanding of CF treatment in a real-world context.
Competitiondate
202402
Approvedterm2
1 yr 0 mth
Pinamesdelim
Jafari, Mehdi
Approvedterm
1 an 0 mois
Cihrcontribution2
MI #2~ $17,500~ $0~